ReviewBritish journal of haematology2013
Advances in predicting acute GVHD.
Review in British journal of haematology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 105 citations in OpenAlex.
- Trial
- BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient.Blood advances · 2019Trial
- Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine.Blood advances · 2018Trial
- Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2016Trial
- Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy.Haematologica · 2015Trial
- Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation.Bone marrow transplantation · 2015Trial
- [Fecal microbiota transplantation attenuates gastrointestinal inflammation in murine acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation by inhibiting RIPK1/RIPK3-mediated necroptosis].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- Article
- DecodingAcute GVHD: The role of serum biomarkers and imaging in diagnosis and management.Blood reviews · 2025Review
- Interleukin Networks in GVHD: Mechanistic Crosstalk, Therapeutic Targeting, and Emerging Paradigms.International journal of molecular sciences · 2025Review
- Burden, resources, and needs of patients with severe graft-versus-host disease - A qualitative study.Palliative & supportive care · 2025Article
- Article
- Graft-Versus-Host Disease: Can Biomarkers Assist in Differential Diagnosis, Prognosis, and Therapeutic Strategy?Pharmaceuticals (Basel, Switzerland) · 2024Review
- Monocytes as an early risk factor for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Frontiers in immunology · 2024Article
- Assessment of risk factors for acute graft-Therapeutic advances in hematology · 2023Article
- Impact of total marrow/lymphoid irradiation dose to the intestine on graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for hematologic malignancies.Frontiers in oncology · 2022Article
- Roles of the intestinal microbiota and microbial metabolites in acute GVHD.Experimental hematology & oncology · 2021Review
- Burden and Needs of Patients with Severe GvHD from the Supportive and Palliative Care Perspective-A Literature Review.Cancers · 2021Review
- Assessment of ST2 and Reg3a levels in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantationTurkish journal of medical sciences · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Acute graft-versus-host disease (GVHD) is a leading cause of non-relapse mortality following allogeneic haematopoietic cell transplantation. Attempts to improve treatment response in clinically-established GVHD have not improved overall survival, often due to the increased risk of infectious complications. Alternative approaches to decrease GVHD-related morbidity and mortality have focused on the ability to predict GVHD prior to clinical manifestation in an effort to provide an opportunity to abort GVHD development, and to gain new insights into GVHD pathophysiology. This review outlines the research efforts to date that have identified clinical and laboratory-based factors that are predictive of acute GVHD and describes future directions in developing algorithms that will improve the ability to predict the development of clinically relevant GVHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.